journal article·2025-04Open access

YIGSR Functionalized Hybrid Exosomes Spatially Target Dasatinib to Laminin Receptors for Precision Therapy in Breast Cancer

Pratiksha Tiwari, Ravi Prakash Shukla, Krishna Yadav, Madhu Sharma, Avijit Kumar Bakshi, Dilip Panwar, Neha Singh, Neha Agarwal, Madhav Nilakanth Mugale, Prabhat Ranjan Mishra

Advanced Healthcare Materials· Volume 14· Issue 9

Abstract

Abstract In this study, YIGSR‐functionalized exosomes (Exo) are engineered and hybridized with lipid polymeric nanoparticles (LPNPs) followed by loading of chemotherapy Dasatinib (DST) to spatially target laminin receptors on tumors. Exo derived from differentiated macrophages are engineered with YIGSR targeting peptides.These YIGSR‐Exo are subsequently fused with LPNPs membranes using the freeze‐thaw method, resulting in fused hybrid YIGSR‐Exo, which are then loaded with DST, creating DST‐FuNP@YIGSR‐Exo and targeted breast cancer (BC), leading to enhanced mitochondrial membrane potential (54.50 ±5.0%), increased reactive oxygen species (59.50 ± 6.0%), and apoptosis (63 ± 6.5%), ultimately inducing cell death. Further, cellular uptake and receptor blocking studies confirm the binding affinity and interaction of DST‐FuNP@YIGSR‐Exo with laminin receptors, Intravenous pharmacokinetic analysis of DST‐FuNP@YIGSR‐Exo reveals a significant improvement in AUC0‐∞, with a 20.84‐fold increase compared to free DST and a 1.61‐fold enhancement over DST‐FuNP@Exo. This is further supported by in vivo imaging and demonstrated improved tumor localization. A tumor regression study shows a 6.8‐fold reduction in tumors. Tumor tissue‐specific IHC for the Ki67 proliferative marker is significantly reduced in the targeted formulation. The potential of DST‐FuNP@YIGSR‐Exo as an effective carrier for delivering chemotherapeutic drugs, paving the path for the advancement of biologically obtained nanocarriers for targeted breast cancer.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Extracellular vesicles in disease · RNA Interference and Gene Delivery · Cell Adhesion Molecules Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Pharmaceutics and Pharmacokinetics CSIR‐Central Drug Research Institute Lucknow Uttar Pradesh 226031 India

Division of Toxicology and Experimental Medicine CSIR‐Central Drug Research Institute Lucknow Uttar Pradesh 226031 India

Academy of Scientific and Innovation Research (AcSIR) Ghaziabad Uttar Pradesh 201002 India

References (61)

Show source-provided references
1. 10.1016/j.jmgm.2024.10870210.1016/j.jmgm.2024.108702 ↗
2. 10.1039/C8TB03351J10.1039/C8TB03351J ↗
3. 10.1007/s10549-006-9463-x10.1007/s10549-006-9463-x ↗
4. 10.1016/j.jconrel.2022.04.00710.1016/j.jconrel.2022.04.007 ↗
5. 10.1007/s10549-008-0271-310.1007/s10549-008-0271-3 ↗
6. 10.1080/20013078.2017.134408710.1080/20013078.2017.1344087 ↗
7. 10.1016/j.jconrel.2023.09.01610.1016/j.jconrel.2023.09.016 ↗
8. 10.1002/pmic.20080010910.1002/pmic.200800109 ↗
9. 10.1124/pr.112.00598310.1124/pr.112.005983 ↗
10. 10.1517/13543784.2013.79330810.1517/13543784.2013.793308 ↗
11. 10.1038/s41416-018-0287-310.1038/s41416-018-0287-3 ↗
12. 10.1039/C5BM00161G10.1039/C5BM00161G ↗
13. 10.2174/09298670878513283410.2174/092986708785132834 ↗
14. 10.1002/advs.20200051510.1002/advs.202000515 ↗
15. 10.1038/srep2193310.1038/srep21933 ↗
16. 10.1016/j.actbio.2019.05.05410.1016/j.actbio.2019.05.054 ↗
17. 10.1016/j.colsurfb.2024.11424710.1016/j.colsurfb.2024.114247 ↗
18. 10.3109/10717544.2010.49024910.3109/10717544.2010.490249 ↗
19. 10.1002/adfm.20170736010.1002/adfm.201707360 ↗
20. 10.1038/s41551-018-0254-610.1038/s41551-018-0254-6 ↗
21. Y.‐H.Kim S.‐B.Yong J. Y.Chung S. S.Kim J. H.Kim H. R. A.Se Dual‐Targeting Lipid‐Polymer Hybrid Nanoparticles2021.
22. 10.1016/j.abb.2024.11002210.1016/j.abb.2024.110022 ↗
23. Jung M. K. · J. Vis. Exp. · 2018 · 2018 · 5
24. 10.1039/C6RA11260A10.1039/C6RA11260A ↗
25. 10.1021/acsami.7b1910910.1021/acsami.7b19109 ↗
26. 10.1021/acsami.7b1869910.1021/acsami.7b18699 ↗
27. 10.1016/j.biomaterials.2018.08.01610.1016/j.biomaterials.2018.08.016 ↗
28. 10.1016/j.jddst.2020.10208510.1016/j.jddst.2020.102085 ↗
29. 10.1007/978-981-97-3925-7_610.1007/978-981-97-3925-7_6 ↗
30. 10.1016/j.msec.2017.03.13010.1016/j.msec.2017.03.130 ↗
31. 10.3390/jpm1106055910.3390/jpm11060559 ↗
32. 10.1016/j.jconrel.2023.11.00510.1016/j.jconrel.2023.11.005 ↗
33. 10.1021/acsnano.9b0465110.1021/acsnano.9b04651 ↗
34. 10.1016/j.msec.2019.01.12310.1016/j.msec.2019.01.123 ↗
35. 10.3390/pharmaceutics1408152310.3390/pharmaceutics14081523 ↗
36. 10.1039/D0BM01033B10.1039/D0BM01033B ↗
37. 10.1016/j.bioadv.2023.21367210.1016/j.bioadv.2023.213672 ↗
38. 10.1039/C7NR04425A10.1039/C7NR04425A ↗
39. 10.1016/j.bbrep.2023.10151410.1016/j.bbrep.2023.101514 ↗
40. 10.1158/1078-0432.CCR-06-111210.1158/1078-0432.CCR-06-1112 ↗
41. 10.1007/s10337-020-03920-010.1007/s10337-020-03920-0 ↗
42. 10.7150/thno.2107410.7150/thno.21074 ↗
43. 10.1039/C9BM01246J10.1039/C9BM01246J ↗
44. 10.1073/pnas.171296311510.1073/pnas.1712963115 ↗
45. 10.1016/j.ijpharm.2024.12423410.1016/j.ijpharm.2024.124234 ↗
46. 10.3390/ijms1901019510.3390/ijms19010195 ↗
47. 10.1016/j.jconrel.2024.06.00910.1016/j.jconrel.2024.06.009 ↗
48. 10.1186/s12951-021-00986-210.1186/s12951-021-00986-2 ↗
49. 10.3390/pharmaceutics1311193510.3390/pharmaceutics13111935 ↗
50. 10.1021/acs.molpharmaceut.2c0067310.1021/acs.molpharmaceut.2c00673 ↗
51. 10.1016/j.blre.2012.12.00210.1016/j.blre.2012.12.002 ↗
52. 10.1016/j.jconrel.2014.07.04910.1016/j.jconrel.2014.07.049 ↗
53. 10.1039/C9BM00221A10.1039/C9BM00221A ↗
54. 10.1016/j.actbio.2020.06.02310.1016/j.actbio.2020.06.023 ↗
55. 10.1016/j.colsurfb.2023.11331610.1016/j.colsurfb.2023.113316 ↗
56. 10.1002/adhm.20180030010.1002/adhm.201800300 ↗
57. 10.3390/cancers1110156010.3390/cancers11101560 ↗
58. 10.7150/thno.2943110.7150/thno.29431 ↗
59. 10.1016/j.colsurfb.2017.04.02810.1016/j.colsurfb.2017.04.028 ↗
60. 10.1016/j.saa.2021.11998710.1016/j.saa.2021.119987 ↗
61. 10.1021/acsami.6b0895810.1021/acsami.6b08958 ↗